Metabolic defects shared by Alzheimer's disease and diabetes: A focus on mitochondria

Curr Opin Neurobiol. 2023 Apr:79:102694. doi: 10.1016/j.conb.2023.102694. Epub 2023 Feb 24.

Abstract

Type 2 diabetes (T2D) and Alzheimer's disease (AD) are two global epidemics that share several metabolic defects, such as insulin resistance, impaired glucose metabolism, and mitochondrial defects. Importantly, strong evidence demonstrates that T2D significantly increases the risk of cognitive decline and dementia, particularly AD. Here, we provide an overview of the metabolic defects that characterize and link both pathologies putting the focus on mitochondria. The biomarker potential of mitochondrial components and the therapeutic potential of some drugs that target and modulate mitochondria are also briefly discussed.

Keywords: Alzheimer's disease; diabetes; metabolic disorders; mitochondria; mitochondrial biomarkers and therapies.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease* / pathology
  • Biomarkers / metabolism
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / epidemiology
  • Diabetes Mellitus, Type 2* / metabolism
  • Humans
  • Mitochondria / metabolism

Substances

  • Biomarkers